Liver International最新文献

{"title":"Viability Assessment During Normothermic Machine Liver Perfusion: A Literature Review","authors":"Heithem Jeddou,&nbsp;Stylianos Tzedakis,&nbsp;Mohamed Ali Chaouch,&nbsp;Laurent Sulpice,&nbsp;Michel Samson,&nbsp;Karim Boudjema","doi":"10.1111/liv.16244","DOIUrl":"10.1111/liv.16244","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objective</h3>\u0000 \u0000 <p>The discrepancy between donor organ availability and demand leads to a significant waiting-list dropout rate and mortality. Although quantitative tools such as the Donor Risk Index (DRI) help assess organ suitability, many potentially viable organs are still discarded due to the lack of universally accepted markers to predict post-transplant outcomes. Normothermic machine perfusion (NMP) offers a platform to assess viability before transplantation. Thus, livers considered unsuitable for transplantation based on the DRI can be evaluated and potentially transplanted. During NMP, various viability criteria have been proposed. These criteria are neither homogeneous nor consensual. In this review, we aimed to describe the viability criteria during NMP and evaluate their ability to predict hepatic graft function following transplantation. We conducted a PubMed search using the terms ‘liver transplantation’, ‘normothermic machine perfusion’ and ‘assessment’, including only English publications up to February 2024. Viability assessment during NMP includes multiple hepatocellular and cholangiocellular criteria. Lactate clearance and bile production are commonly used indicators, but their ability to predict post-transplant outcomes varies significantly. The predictive value of cholangiocellular criteria such as bile pH, bicarbonate and glucose levels remains under investigation. Novel markers, such as microRNAs and proteomic profiles, offer the potential to enhance graft evaluation accuracy and provide insights into the molecular mechanisms underlying liver viability. Combining perfusion parameters with biomarkers may improve the prediction of long-term graft survival. Future research should focus on standardising viability assessment protocols and exploring real-time biomarker evaluations, which could enhance transplantation outcomes and expand the donor pool.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential and Challenges of Autophagy in the Treatment of Liver Fibrosis","authors":"Jia Chen,&nbsp;Qichang Xing","doi":"10.1111/liv.16168","DOIUrl":"10.1111/liv.16168","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug-Induced Liver Injury and Autoimmune Hepatitis","authors":"Yu Wang,&nbsp;Xuhui Lin,&nbsp;Ying Sun,&nbsp;Jimin Liu,&nbsp;Jia Li,&nbsp;Qiuju Tian,&nbsp;Feng Guo,&nbsp;Xiaoli Hu,&nbsp;Liang Wang,&nbsp;Pingying Li,&nbsp;Jingshou Chen,&nbsp;Yan Wang,&nbsp;Zikun Ma,&nbsp;Jidong Jia,&nbsp;Jing Zhang,&nbsp;Zhengsheng Zou,&nbsp;Xinyan Zhao","doi":"10.1111/liv.16239","DOIUrl":"10.1111/liv.16239","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Discriminating between idiosyncratic drug-induced liver injury (DILI) and autoimmune hepatitis (AIH) is critical yet challenging. We aim to develop and validate a machine learning (ML)-based model to aid in this differentiation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter cohort study utilised a development set from Beijing Friendship Hospital, with retrospective and prospective validation sets from 10 tertiary hospitals across various regions of China spanning January 2009 to May 2023. Different ML algorithms were tested using 24 routine laboratory parameters. The Shapley Additive exPlanations (SHAP) analysis was used to evaluate the contribution of each parameter in the ML model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 2554 patients (1750 for DILI and 804 for AIH) were included. Using Gradient Boost Decision Tree algorithm, five key parameters—aspartate transaminase, globulin, prealbumin, creatinine and platelet count—were selected to construct the ML model. Consequently, a web-based tool named Beijing-AID (BJ-AID) was developed (http://43.143.153.225:5000/). The BJ-AID model demonstrated excellent discrimination performance, with an area under the receiver operating characteristic curve (AUROC) of 0.94 (95% CI, 0.902–0.975) in the development set, 0.91 (95% CI, 0.900–0.928) in all external validation sets and 0.93 (95% CI, 0.889–0.974) in a prospective validation set. Notably, the BJ-AID model also effectively discriminated atypical cases, including drug-induced autoimmune-like hepatitis and AIH with the history of drug consumption, achieving an AUROC = 0.85 (95% CI, 0.742–0.949).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We successfully developed and validated a machine learning-based model, BJ-AID, which exhibits a strong discrimination performance. BJ-AID can assist practitioners and hepatologists in diagnosing both typical and atypical cases of DILI and AIH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT05532345</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Copper in PSVD: When Having the Tool Doesn't Mean Necessarily Using It","authors":"Zoe Mariño,&nbsp;Virginia Hernández-Gea","doi":"10.1111/liv.16228","DOIUrl":"10.1111/liv.16228","url":null,"abstract":"&lt;p&gt;We have read with great interest the paper by Balcar L, Dominik N, et al., titled ‘Elevated Hepatic Copper Content in Porto-Sinusoidal Vascular Disorder (PSVD): Leading Down a Wrong Track.’ The study evaluates copper liver content in patients with PSVD and intriguingly reports elevated hepatic copper levels, which were associated with a higher degree of decompensation. However, the study sample was poorly characterised, and the rationale for ruling out Wilson disease (WD) as a differential diagnosis remains particularly unclear.&lt;/p&gt;&lt;p&gt;This work could be considered a long-term addendum into Peter Ferenci's legacy manuscript from 2005 [&lt;span&gt;1&lt;/span&gt;] performed by the same group in Vienna 20 years ago. In that classic work, 359 liver biopsies from 114 patients WD, 219 non-cholestatic liver disease and 22 healthy controls had their intrahepatic copper measurement performed and compared, in an attempt to define intrahepatic copper value as a diagnostic tool for WD. Their main figure on that article could be complemented by the results from the present study (see adapted Figure 1), in which 92 patients with a known diagnosis of PSVD, had their intrahepatic copper content systematically evaluated as well. Despite the median copper values were low, as expected for a non-WD cohort (30 μg/g dry weight, IQR: 18–55), four patients (4.3%) presented with very increased intrahepatic copper levels (over the stablished cutoff for high suspicion of WD, ≥ 250 μg/g) and 29 (32%) with intermediate levels above normality (≥ 50 μg/g but &lt; 250 μg/g), leading the authors to suggest PSVD should be included in the differential diagnosis whenever a patient presents with high copper levels in hepatic tissue. The opposite lecture would be that high levels of intrahepatic copper content would suggest PSVD in the absence of WD confirmation, being copper a negative predictor for worse prognosis. A third lecture would account for the magnified value of potential outliers in this scenario. And a forth lecture would really question the need for such a measurement, only explained by unlimited access to this tool irrespectively of clinical suspicion in a highly experienced centre for WD.&lt;/p&gt;&lt;p&gt;Adapted Figure 1 from Ferenci et al. [&lt;span&gt;1&lt;/span&gt;] (figure 2 in the original manuscript).&lt;/p&gt;&lt;p&gt;A thorough clinical history would likely negate the need for measuring copper content in the majority of patients. In most cases, the diagnosis of WD could be excluded through ceruloplasmin levels and 24-h urinary copper measurements, at least in symptomatic patients with advanced liver disease [&lt;span&gt;2, 3&lt;/span&gt;], like those from the present work. In fact, the need for a liver biopsy (LB) in this clinical scenario of WD suspicion would be minimal for different reasons: (1) patients with WD have no pathognomonic signs on regular histology and often show ‘common signs of cirrhosis’ whenever cirrhosis is clinically evident [&lt;span&gt;4&lt;/span&gt;]—minimising the potential confusion between these two ","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/liv.16228","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Hepatic Copper Content in Porto-Sinusoidal Vascular Disorder (PSVD): Leading Down a Wrong Track","authors":"Lorenz Balcar,&nbsp;Nina Dominik,&nbsp;Behrang Mozayani,&nbsp;Georg Semmler,&nbsp;Emina Halilbasic,&nbsp;Mattias Mandorfer,&nbsp;Thomas Reiberger,&nbsp;Michael Trauner,&nbsp;Bernhard Scheiner,&nbsp;Albert Friedrich Stättermayer","doi":"10.1111/liv.16175","DOIUrl":"10.1111/liv.16175","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Porto-sinusoidal vascular disorder (PSVD) is a rare vascular liver disorder characterised by specific histological findings in the absence of cirrhosis, which is poorly understood in terms of pathophysiology. While elevated hepatic copper content serves as diagnostic hallmark in Wilson disease (WD), hepatic copper content has not yet been investigated in PSVD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with a verified diagnosis of PSVD at the Medical University of Vienna and available hepatic copper content at the time of diagnosis of PSVD were retrospectively included. Elevated hepatic copper content was correlated with cholestatic changes and WD diagnostics in PSVD and analysed for liver-related outcomes (first/further hepatic decompensation/liver-related death).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 92 patients were included into this study (mean age 49 ± 16; 57% male; median hepatic copper content was 30 [IQR: 18–55] μg/g) of whom 29 (32%) had moderately (≥ 50 μg/g) and 4 (4%) strongly (≥ 250 μg/g) elevated hepatic copper content.</p>\u0000 \u0000 <p>Elevated levels of hepatic copper were associated with younger age in multivariable linear regression analysis. After adjusting for age, decompensation status and albumin, hepatic copper content was significantly associated with the outcome of interest (log, per 10; aHR: 1.60 [95% CI: 1.14–2.25]; <i>p</i> = 0.007). A hepatic copper cut-off at ≥ 90 μg/g identified PSVD patients with considerable risk of liver-related outcomes (at 2 years: 51% vs. 12%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Elevated hepatic copper seems frequent in patients with PSVD even in the absence of cholestatic features, especially in young patients, which makes differential diagnosis to WD challenging. Since PSVD patients with elevated hepatic copper content had increased risk for liver-related outcomes, the pathomechanisms underlying hepatic copper accumulation in PSVD should be investigated as this may open new therapeutic avenues.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice","authors":"Cristina Di Giorgio,&nbsp;Ginevra Urbani,&nbsp;Silvia Marchianò,&nbsp;Michele Biagioli,&nbsp;Martina Bordoni,&nbsp;Rachele Bellini,&nbsp;Carmen Massa,&nbsp;Ginevra Lachi,&nbsp;Luigi Cari,&nbsp;Elva Morretta,&nbsp;Lucio Spinelli,&nbsp;Maria Chiara Monti,&nbsp;Valentina Sepe,&nbsp;Angela Zampella,&nbsp;Eleonora Distrutti,&nbsp;Jesus M. Banales,&nbsp;Ainhoa Lapitz,&nbsp;Piotr Milkiewicz,&nbsp;Malgorzata Milkiewicz,&nbsp;Stefano Fiorucci","doi":"10.1111/liv.16235","DOIUrl":"10.1111/liv.16235","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterised by progressive biliary inflammation and fibrosis, leading to liver cirrhosis and cholangiocarcinoma. GPBAR1 (TGR5) is a G protein-coupled receptor for secondary bile acids. In this study, we have examined the therapeutic potential of BAR501, a selective GPBAR1 agonist in a PSC model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Single-cell analysis of healthy human liver samples and gene expression analysis of PSC liver samples were conducted. In vitro studies on a human cholangiocyte cell line (NHC), U937 and human hepatic stellate cells (hSteCs) were performed. Additionally, <i>Abcb4</i>^{<i>−/−</i>} mice were treated with BAR501 for 12–24 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Single-cell analysis demonstrated that <i>GPBAR1</i> is expressed by macrophages, NK cells, sinusoidal cells and to a lesser extent by cholangiocytes. Total liver expression of <i>GPBAR1</i> increases in PSC patients compared to that in healthy controls and positively correlates with markers for monocytes and NK cells and cytokeratin 19. In vitro treatment of NHCs with BAR501 reversed the acquisition of a pro-inflammatory phenotype and the downregulation of <i>GPBAR1</i> expression promoted by LPS in an NF-κB-dependent manner. Treating <i>Abcb4</i>^{<i>−/−</i>} mice reduced bile duct inflammation and liver fibrosis and prevented the downregulation of GPBAR1 expression. Treating mice with BAR501 also modulated the bile acid pool composition and reduced the dysbiosis-associated gut permeability, and intestinal and systemic inflammation. Ex vivo experiments using conditioned media from BAR501-treated cholangiocytes mitigated the activation of macrophages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study provides evidence for the therapeutic potential of selective GPBAR1 agonists in intestinal inflammation–associated cholestasis, warranting the evaluation of BAR501 in PSC patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11727439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Injury due to Intravenous Methylprednisolone in the Drug-Induced Liver Injury Network","authors":"Jawad Ahmad,&nbsp;Yi-Ju Li,&nbsp;Elizabeth Phillips,&nbsp;Andrew Dellinger,&nbsp;Paul H. Hayashi,&nbsp;Naga Chalasani,&nbsp;Robert J. Fontana,&nbsp;David E. Kleiner,&nbsp;Huiman X. Barnhart,&nbsp;Jay H. Hoofnagle,&nbsp;the Drug-Induced Liver Injury Network","doi":"10.1111/liv.16242","DOIUrl":"10.1111/liv.16242","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Short courses of intravenous (iv) methylprednisolone (MP) can cause drug induced liver injury (DILI). The aim of this study was to assess the clinical features and HLA associations of MP-related DILI enrolled in the US DILI Network (DILIN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>DILIN cases with MP as a suspected drug were reviewed. DILIN causality scoring was assigned on a 5-point scale (definite, highly likely, probable, possible, unlikely). All cases with MP causality scores of definite, highly likely or probable were analysed. HLA data from direct sequencing were analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eleven cases of definite, highly likely, or probable MP DILI were identified. The median age was 48 years; 73% were female; median latency to onset was 30 days; 55% were jaundiced; and all had hepatocellular injury with one patient requiring transplantation. Nine of the 11 cases were in patients with multiple sclerosis (MS). Liver biopsies in 7 cases revealed mild acute hepatitis with/without cholestasis. HLA data demonstrated that <i>HLA-DRB1*15</i>:<i>01</i>, the primary HLA class II allele associated with MS was over-represented. <i>HLA-DQB1*06:02-HLA-DQA1*01:02</i> which is haplotypic with the <i>HLA-DRB1</i>*<i>15</i> haplotype was more common in the MP DILI cases compared to other DILI controls (<i>p</i> = 0.03) and to DILI controls exposed to MP (<i>p</i> = 0.04).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MP DILI is characterised by hepatocellular injury, short latency and generally rapid recovery. There was no independent HLA haplotype associated with MP DILI.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Different Impacts of Muscle Mass and Adipose Tissue on Patients With Hepatocellular Carcinoma Undergoing Surgical Resection","authors":"Pei-Chang Lee,&nbsp;Tsung-Yi Cheng,&nbsp;Chun-Ting Ho,&nbsp;Kuo-Wei Huang,&nbsp;Gar-Yang Chau,&nbsp;Yi-Hsiang Huang,&nbsp;Teh-Ia Huo,&nbsp;Ming-Chih Hou,&nbsp;Jaw-Ching Wu,&nbsp;Chien-Wei Su","doi":"10.1111/liv.16237","DOIUrl":"10.1111/liv.16237","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background &amp; Aims</h3>\u0000 \u0000 <p>Body composition is an objective assessment reflecting nutritional status and is highly gender different. Surgical resection, the standard treatment for early-stage hepatocellular carcinoma (HCC), is an energy-consuming major operation that would affect body composition. However, the impacts of body composition on the post-operative prognosis of HCC are still uncertain. In this study, we aimed to investigate surgery-related changes in body composition and the impacts on clinical outcomes of HCC after surgical resection distinguished by gender.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>From January 2013 to December 2018, 401 consecutive patients who received surgical resection for HCC in Taipei Veterans General Hospital were retrospectively reviewed. Cross areas of adipose and muscle mass were measured at L3 vertebral level from peri-operative computed tomography by Slice-O-matic software; body composition indices were thus calculated. Factors associated with survivals were analysed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Body composition indices did not change significantly after surgical resection of HCC in both males and females. Higher pre-operative intramuscular adipose tissue index (IMATI) (hazard ratio [HR]: 2.059, <i>p</i> = 0.002) and lower ratio of subcutaneous to visceral adipose tissue index (SATI/VATI) (HR: 1.681, <i>p</i> = 0.028) were independent predictors of worse overall survival (OS) in male patients. In females, higher pre-operative IMATI (HR: 3.053, <i>p</i> = 0.001) was the only body composition-related factor predicting OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Surgical resection contributed minor changes in body composition in patients with early HCC. Myosteatosis and subcutaneous to visceral fat ratio were survival predictors in male patients, but myosteatosis was the only body composition-predictor of survival in females.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort","authors":"Delplanque Marion,&nbsp;Amiot Xavier,&nbsp;Wendum Dominique,&nbsp;Rodrigues François,&nbsp;Zohra Aknouche,&nbsp;Rim Bourguiba,&nbsp;Terris Benoit,&nbsp;Duvoux Christophe,&nbsp;Bedossa Pierre,&nbsp;Lebrec Didier,&nbsp;Sogni Philippe,&nbsp;Parlati Lucia,&nbsp;Charlotte Frederic,&nbsp;Ratziu Vlad,&nbsp;Mouly Stéphane,&nbsp;Augustin Jeremy,&nbsp;Calderaro Julien,&nbsp;Scoazec Giovanna,&nbsp;Vignaud Jean Michel,&nbsp;Seyrig Jacques Arnaud,&nbsp;Grateau Gilles,&nbsp;Savey Léa,&nbsp;Georgin-Lavialle Sophie","doi":"10.1111/liv.16232","DOIUrl":"10.1111/liv.16232","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with <i>MEFV</i> mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to evaluate liver involvement in FMF patients at a French tertiary centre for adult FMF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted an observational study with FMF patients displaying 2 pathogenic <i>MEFV</i> mutations at the National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) in Paris and included in the JIR cohort. <i>MEFV</i> heterozygous patients and those with other liver disease causes were excluded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 533 FMF patients 12.4% had chronic liver abnormalities, with 30% who developed cirrhosis 54 years [36–57] in median after disease onset. Forty-seven per cent were colchicine resistant, and 41% received interleukin-1 inhibitors. Cirrhotic patients experienced delayed hepatopathy diagnosis, prolonged FMF diagnosis delay and late-onset treatment initiation compared to those with only liver function test abnormalities. Colchicine resistance and interleukin-1 inhibitor use were more common in cirrhotic patients. Body mass index and AA amyloidosis rates did not differ significantly between groups. Twenty-one patients had undergone liver biopsies including 14 cirrhotic patients revealing steatohepatitis in 12 cases and probable steatohepatitis in 4. Other lesions, like iron overload and sinusoidal dilatation, were sporadically observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>FMF patients are at risk of chronic liver disease. Regular liver function monitoring is crucial, particularly in case of persistent inflammation, due to the risk of progression to cirrhosis and its associated morbidity and mortality.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Portal Hypertension Following Embolisation of a Spontaneous Portal Shunt","authors":"Hong-bin Zhu,&nbsp;Qing-chen Wang,&nbsp;Guang-chuan Wang,&nbsp;Chun-qing Zhang","doi":"10.1111/liv.16227","DOIUrl":"10.1111/liv.16227","url":null,"abstract":"","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 2","pages":""},"PeriodicalIF":6.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}